Mirus Bio receives ISO 13485:2016 certification, underscoring the quality of processes used to support GMP product portfolio. Read more

mirus bio logo

TransduceIT Transduction Reagent – 1 mL

SKU MIR 6620 Categories ,

$32.00

Description

The TransIT® Lentivirus System combines the novel technologies of the TransIT®-Lenti Transfection Reagent with the Lentivirus Packaging Mix Powered by MISSION® Genomics. Titers of 10can be achieved with an optimized protocol. Whether you’re a novice or an expert, you can rely on these benefits:

  • Produce 2-3x higher functional titers than Lipofectamine® 2000 & 3000
  • Achieve even higher titers and eliminate the need to concentrate
  • No media change required, single harvest

 

SKU: MIR 6620

Supporting Data

TransIT® Lentivirus System Configurations

TransIT® Lentivirus System Component
Product No.
Component Quantity
MIR 6650 MIR 6603 TransIT®-Lenti Transfection Reagent 0.3 ml
MIR 6630 Lentivirus Packaging Mix Powered by MISSION® 5 rxn (0.25 ml)
MIR 6620 TransduceIT™ Reagent 1 ml
MIR 6655 MIR 6600 TransIT®-Lenti Transfection Reagent 1.5 ml
MIR 6640 Lentivirus Packaging Mix Powered by MISSION® 34 rxn (1.7 ml)
MIR 6620 TransduceIT™ Reagent 1 ml

Up to 100-fold Increase in Functional Lentivirus Titers. Adherent 293T/17 cells were transfected in a 6-well plate with the pLKO.1-puro-CMV-TurboGFP™ transfer vector and the Lentivirus Packaging Mix Powered by MISSION® Genomics or pLenti6.2-GW/EmGFP transfer vector and the ViraPower™ Lentiviral Packaging Mix (1:1 ration, 2 µg/well) with the following reagents: TransIT®-Lenti (3:1, vol:wt), Lipofectamine® 2000 (3:1), or Lipofectamine® 3000 (3:1:1). The supernatant was harvested, filtered (0.45 µm), and titered using 293T/17 cells. Lentivirus transductions were performed in the presence of 8 µg/ml TransduceIT™ and GFP expression was measured 72 hours post-transduction using guava easyCyte™ 5HT Flow Cytometer. Error bars represent triplicate transfection complexes titered individually. Functional titers were calculated using virus dilutions with less than 20% GFP positive cells.

Transfer Vector Selection Greatly Affects Functional Lentivirus Titers. Adherent 293T/17 cells were transfected in a 6-well plate with one of three transfer vectors: MISSION® pLKO.1-puro-CMV-TurboGFP™, ViraPower™ pLenti6.2-GW/EmGFP, or Precision Lenti-ORF™ RFP and the Lentivirus Packaging Mix powered by MISSION® Genomics) (1:1 ratio, 2 µg/well) using the TransIT®-Lenti Transfection Reagent (3:1, vol:wt). The supernatant was harvested, filtered (0.45 µm), and titered using 293T/17 cells. Lentivirus transductions were performed in the presence of 8 µg/ml TransduceIT™ and GFP expression was measured 72 hours post-transduction using guava easyCyte™ 5HT Flow Cytometer. Error bars represent triplicate transfection complexes titered individually. Functional titers were calculated using virus dilutions with less than 20% GFP positive cells.

Resources

Specifications

Storage Conditions
Lentivirus Packaging Mix Powered by MISSION® Genomics: Multiple storage conditions – see individual bottles for specific recommendations
TransIT® Lentivirus System: Store at -20°C
TransduceIT™ Transduction Reagent: Store at -20°C

Product Guarantee
Lentivirus Packaging Mix Powered by MISSION® Genomics: 1 year
TransIT® Lentivirus System: As labeled on the product components
TransduceIT™ Transduction Reagent: 6 months

Usage Statement
All Configurations: For Research Use Only.

Animal Origin Statement
All Configurations: This product is animal origin free.

 

Technical Product Literature

Full Protocol
TransIT® Lentivirus System Full Protocol (PDF)

Quick Reference Protocol
TransIT® Lentivirus System Quick Ref Protocol (PDF)

Product Data Sheets
Lentivirus Packaging Mix Product Data Sheet (PDF)
TransduceIT™ Reagent Product Data Sheet (PDF)

SDS
Lentivirus Packaging Mix SDS (PDF)
TransduceIT™ Reagent SDS (PDF)
TransIT® Lentivirus System SDS (PDF)

FAQs

See the TransIT-Lentivirus System FAQs

Using transfection reagents and enhancers from Mirus has given our platform a competitive advantage. Increasing efficiency and lowering costs for all of our porgrams.

 

Sally Mader, PhD
ZYZ Theraputics